Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Metabolomics Market - Size, Share, Trends, and Forecast 2026-2032 | AI, Multi-Omics, and Precision Medicine Drive 11.76% CAGR Toward USD 7.39 Billion

globenewswire.com

Global Metabolomics Market - Size, Share, Trends, and Forecast 2026-2032 | AI, Multi-Omics, and Precision Medicine Drive 11.76% CAGR Toward USD 7.39 Billion Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Metabolomics Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.

The global metabolomics market research report examines a sector projected to grow from USD 3.78 billion in 2026 to USD 7.39 billion by 2032, representing a CAGR of 11.76%. It provides strategic insights into technologies, applications, adoption drivers, regional activity, artificial intelligence, and competitive priorities shaping metabolomics across healthcare, pharmaceuticals, nutrition, agriculture, toxicology, and environmental science.

Market Overview and Growth Drivers

Metabolomics measures small-molecule metabolites to reveal real-time biochemical activity influenced by genetics, microbiome composition, diet, medication, lifestyle, and environmental exposure. Its ability to characterize phenotype, disease progression, treatment response, and cellular metabolism is strengthening its role in systems biology and precision medicine.

Key demand drivers include:

The analysis helps decision-makers identify high-growth applications and align investment priorities with emerging clinical, scientific, and commercial opportunities.

Technology and Market Transformation

High-resolution mass spectrometry, nuclear magnetic resonance spectroscopy, liquid and gas chromatography, capillary electrophoresis, stable isotope tracing, and advanced bioinformatics are expanding analytical coverage. Targeted metabolomics supports precise pathway quantification, while untargeted approaches enable broad biomarker discovery.

Major shifts include:

These insights support technology selection, partnership evaluation, and differentiated market-entry strategies.

Artificial Intelligence in Metabolomics

Artificial intelligence is improving peak detection, feature alignment, spectral deconvolution, noise reduction, metabolite annotation, pathway interpretation, and predictive modeling. Machine learning can identify metabolic signatures associated with disease, therapeutic response, nutritional status, toxic exposure, and microbial activity.

Successful adoption depends on curated libraries, high-quality metadata, independent validation, explainability, bias assessment, and model monitoring. Combining automated analysis with biochemical and clinical expertise offers the strongest pathway from raw spectra to actionable findings.

Regional and Economic Group Insights

ASEAN, GCC, EU, BRICS, G7, and NATO markets display distinct research priorities and infrastructure maturity. Country-level coverage highlights leading activity in the United States, Canada, Mexico, Brazil, the United Kingdom, Germany, France, Russia, Italy, Spain, China, India, Japan, Australia, and South Korea. Regional comparisons enable organizations to assess expansion opportunities while mitigating infrastructure, regulatory, and workforce risks.

Strategic Priorities for Market Participants

Key Takeaways from This Report

Key Attributes:

Key Topics Covered:

1. Preface

1.1. Objectives of the Study

1.2. Market Definition

1.3. Market Segmentation & Coverage

1.4. Years Considered for the Study

1.5. Currency Considered for the Study

1.6. Language Considered for the Study

1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction

2.2. Research Design

2.2.1. Primary Research

2.2.2. Secondary Research

2.3. Research Framework

2.3.1. Qualitative Analysis

2.3.2. Quantitative Analysis

2.4. Market Size Estimation

2.4.1. Top-Down Approach

2.4.2. Bottom-Up Approach

2.5. Data Triangulation

2.6. Research Outcomes

2.7. Research Assumptions

2.8. Research Limitations

3. Executive Summary

3.1. Introduction

3.2. CXO Perspective

3.3. New Revenue Opportunities

3.4. Next-Generation Business Models

3.5. Industry Roadmap

4. Market Overview

4.1. Introduction

4.2. Industry Ecosystem & Value Chain Analysis

4.2.1. Supply-Side Analysis

4.2.2. Demand-Side Analysis

4.2.3. Stakeholder Analysis

4.3. Market Dynamics

4.3.1. Key Drivers

4.3.2. Key Restraints

4.3.3. Key Opportunities

4.3.4. Key Challenges

4.4. Porter's Five Forces Analysis

4.5. PESTLE Analysis

4.6. Market Outlook

4.6.1. Near-Term Market Outlook (0-2 Years)

4.6.2. Medium-Term Market Outlook (3-5 Years)

4.6.3. Long-Term Market Outlook (5-10 Years)

4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective

5.2. Consumer Experience Benchmarking

5.3. Opportunity Mapping

5.4. Distribution Channel Analysis

5.5. Pricing Trend Analysis

5.6. Regulatory Compliance & Standards Framework

5.7. ESG & Sustainability Analysis

5.8. Disruption & Risk Scenarios

5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Metabolomics Market, by Component

7.1. Introduction

7.2. Bioinformatics Tools & Services

7.2.1. Bioinformatics Services

7.2.2. Bioinformatics Tools & Databases

7.3. Metabolomic Instruments

7.3.1. Detection Tools

7.3.1.1. Mass Spectrometry

7.3.1.2. Nuclear Magnetic Resonance Spectroscopy

7.3.1.3. Surface-based Mass Analysis

7.3.2. Separation Tools

7.3.2.1. Capillary Electrophoresis

7.3.2.2. Gas Chromatography

7.3.2.3. High-Performance Liquid Chromatography

7.3.2.4. Ultra Performance Liquid Chromatography

8. Metabolomics Market, by Analytical Approach

8.1. Introduction

8.2. Untargeted Metabolomics

8.3. Semi-Targeted Metabolomics

8.4. Targeted Metabolomics

8.5. Stable-Isotope Tracing And Fluxomics

8.6. Spatial Metabolomics

9. Metabolomics Market, by Sample Type

9.1. Introduction

9.2. Human Biofluids

9.2.1. Blood, Plasma, And Serum

9.2.2. Urine

9.2.3. Cerebrospinal Fluid

9.2.4. Saliva

9.2.5. Breath Condensate And Exhaled Breath

9.3. Animal And Preclinical Samples

9.4. Plant And Agricultural Samples

9.5. Food And Beverage Samples

9.6. Environmental Samples

10. Metabolomics Market, by Indication

10.1. Introduction

10.2. Cardiovascular Disorders

10.3. Metabolic Disorders

10.4. Neurological Disorders

10.5. Oncological Disorders

11. Metabolomics Market, by Application

11.1. Introduction

11.2. Biomarker Discovery

11.2.1. Cancer Biomarkers

11.2.2. Neurological Biomarkers

11.3. Drug Discovery

11.3.1. Metabolic Pathways

11.3.2. Target Identification

11.4. Environmental Science

11.4.1. Pesticide Residue Analysis

11.4.2. Water Quality Analysis

11.5. Nutrigenomics

11.5.1. Cardiovascular Health

11.5.2. Obesity Research

11.6. Personalized Medicine

11.6.1. Genomic Studies

11.6.2. Therapeutic Monitoring

11.7. Toxicology Testing

12. Metabolomics Market, by End-User

12.1. Introduction

12.2. Academic Research Institutes

12.3. Contract Research Organizations

12.4. Pharmaceutical & Biotechnology Companies

13. Metabolomics Market, by Region

13.1. Introduction

13.2. Asia-Pacific

13.3. North America

13.4. Latin America

13.5. Europe

13.6. Middle East

13.7. Africa

14. Metabolomics Market, by Group

14.1. Introduction

14.2. ASEAN

14.3. GCC

14.4. European Union

14.5. BRICS

14.6. G7

14.7. NATO

15. Metabolomics Market, by Country

15.1. Introduction

15.2. United States

15.3. Canada

15.4. Mexico

15.5. Brazil

15.6. United Kingdom

15.7. Germany

15.8. France

15.9. Russia

15.10. Italy

15.11. Spain

15.12. China

15.13. India

15.14. Japan

15.15. Australia

15.16. South Korea

16. Competitive Landscape

16.1. Market Share Analysis, 2025

16.2. Market Concentration Analysis, 2025

16.2.1. Concentration Ratio (CR)

16.2.2. Herfindahl Hirschman Index (HHI)

16.3. Recent Developments & Impact Analysis, 2025

16.4. Product Portfolio Analysis, 2025

16.5. Benchmarking Analysis, 2025

17. Company Profiles

17.1. Advanced Chemistry Development, Inc.

17.2. Advion, Inc.

17.3. Agilent Technologies, Inc.

17.4. Bruker Corporation

17.5. Cayman Chemical Company

17.6. Cerno Bioscience LLC

17.7. Chenomx Inc.

17.8. Clinical Microbiomics A/S

17.9. GERSTEL GmbH & Co. KG

17.10. Hitachi High-Tech Corporation

17.11. Human Metabolome Technologies, Inc.

17.12. JEOL Ltd.

17.13. LECO Corporation

17.14. Lipotype GmbH

17.15. Merck KGaA

17.16. Mestrelab Research S.L.

17.17. Metabolon, Inc.

17.18. metaSysX GmbH

17.19. Nightingale Health Plc

17.20. numares AG

17.21. Owlstone Medical Limited

17.22. Oxford Instruments plc

17.23. QIAGEN N.V.

17.24. Restek Corporation

17.25. Revvity, Inc.

17.26. Sapient Bioanalytics, LLC

17.27. SCION Instruments NL B.V.

17.28. Shimadzu Corporation

17.29. Thermo Fisher Scientific Inc.

17.30. Waters Corporation

18. Key Experts

List of Figures [23]

List of Tables [366]

For more information about this report visit https://www.researchandmarkets.com/r/k98mxm

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.